# An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

> **NCT01273389** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 25 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** CNTO 136
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01273389
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273389, "An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01273389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*